# Biomea Fusion, Inc.: financial statements, quarterly

BMEA · Nasdaq · CIK 1840439 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bmea.md) · [Financials](/companies/bmea/financials.md) · [Filings](/companies/bmea/filings.md) · [Insiders](/companies/bmea/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bmea/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [25.3](/filings/0000950170-25-047775.md) | [30.9](/filings/0000950170-25-047775.md) | [33.8](/filings/0000950170-25-063543.md) | [31.8](/filings/0000950170-25-103041.md) | [27.2](/filings/0001193125-25-264679.md) | [25.2](/filings/0000950170-25-047775.md) | [22.9](/filings/0001193125-26-217074.md) | [16.6](/filings/0001193125-26-335085.md) | [14.4](/filings/0001193125-25-264679.md) | [8.1 d](/filings/0001193125-26-121825.md) | [9.1](/filings/0001193125-26-217074.md) | [9.1](/filings/0001193125-26-335085.md) |
| Operating income | $m | [(31.1)](/filings/0000950170-25-047775.md) | [(37.3)](/filings/0000950170-25-047775.md) | [(41.1)](/filings/0000950170-25-063543.md) | [(38.9)](/filings/0000950170-25-103041.md) | [(34.0)](/filings/0001193125-25-264679.md) | [(30.1)](/filings/0000950170-25-047775.md) | [(29.7)](/filings/0001193125-26-217074.md) | [(21.3)](/filings/0001193125-26-335085.md) | [(20.8)](/filings/0001193125-25-264679.md) | [(11.7) d](/filings/0001193125-26-121825.md) | [(12.8)](/filings/0001193125-26-217074.md) | [(12.8)](/filings/0001193125-26-335085.md) |
| Net income | $m | [(28.4)](/filings/0000950170-25-047775.md) | [(34.9)](/filings/0000950170-25-047775.md) | [(39.1)](/filings/0001193125-25-264679.md) | [(37.3)](/filings/0001193125-25-264679.md) | [(32.8)](/filings/0001193125-25-264679.md) | [(29.3)](/filings/0000950170-25-047775.md) | [(29.3)](/filings/0001193125-26-335085.md) | [(20.7)](/filings/0001193125-26-335085.md) | [(16.4)](/filings/0001193125-25-264679.md) | [4.6 d](/filings/0001193125-26-121825.md) | [(12.4)](/filings/0001193125-26-335085.md) | [(8.3)](/filings/0001193125-26-335085.md) |
| Diluted EPS | $ per share | [(0.80)](/filings/0000950170-25-047775.md) | [(0.98)](/filings/0000950170-25-047775.md) | [(1.09)](/filings/0000950170-25-063543.md) | [(1.03)](/filings/0000950170-25-103041.md) | [(0.91)](/filings/0001193125-25-264679.md) | [(0.81)](/filings/0000950170-25-047775.md) | [(0.80)](/filings/0001193125-26-217074.md) | [(0.51)](/filings/0001193125-26-335085.md) | [(0.27)](/filings/0001193125-25-264679.md) | not reported | [(0.17)](/filings/0001193125-26-217074.md) | [(0.12)](/filings/0001193125-26-335085.md) |
| Basic EPS | $ per share | [(0.80)](/filings/0000950170-25-047775.md) | [(0.98)](/filings/0000950170-25-047775.md) | [(1.09)](/filings/0000950170-25-063543.md) | [(1.03)](/filings/0000950170-25-103041.md) | [(0.91)](/filings/0001193125-25-264679.md) | [(0.81)](/filings/0000950170-25-047775.md) | [(0.80)](/filings/0001193125-26-217074.md) | [(0.51)](/filings/0001193125-26-335085.md) | [(0.27)](/filings/0001193125-25-264679.md) | not reported | [(0.17)](/filings/0001193125-26-217074.md) | [(0.12)](/filings/0001193125-26-335085.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [199](/filings/0000950170-24-118366.md) | [177](/filings/0001193125-26-121825.md) | [145](/filings/0000950170-25-063543.md) | [113](/filings/0000950170-25-103041.md) | [88.0](/filings/0001193125-25-264679.md) | [58.3](/filings/0001193125-26-121825.md) | [35.9](/filings/0001193125-26-217074.md) | [56.2](/filings/0001193125-26-335085.md) | [46.6](/filings/0001193125-25-264679.md) | [55.8](/filings/0001193125-26-335085.md) | [44.7](/filings/0001193125-26-217074.md) | [34.8](/filings/0001193125-26-335085.md) |
| Current assets | $m | [203](/filings/0000950170-23-056381.md) | [179](/filings/0000950170-25-047775.md) | [148](/filings/0000950170-24-052082.md) | [116](/filings/0000950170-24-088584.md) | [93.6](/filings/0000950170-24-118366.md) | [68.3](/filings/0001193125-26-121825.md) | [44.7](/filings/0000950170-25-063543.md) | [64.7](/filings/0000950170-25-103041.md) | [49.4](/filings/0001193125-25-264679.md) | [58.1](/filings/0001193125-26-335085.md) | [46.3](/filings/0001193125-26-217074.md) | [36.4](/filings/0001193125-26-335085.md) |
| Total assets | $m | [225](/filings/0000950170-23-056381.md) | [200](/filings/0000950170-25-047775.md) | [168](/filings/0000950170-24-052082.md) | [136](/filings/0000950170-24-088584.md) | [110](/filings/0000950170-24-118366.md) | [79.9](/filings/0001193125-26-121825.md) | [55.1](/filings/0000950170-25-063543.md) | [73.2](/filings/0000950170-25-103041.md) | [55.2](/filings/0001193125-25-264679.md) | [58.6](/filings/0001193125-26-335085.md) | [46.4](/filings/0001193125-26-217074.md) | [36.9](/filings/0001193125-26-335085.md) |
| Current liabilities | $m | [16.2](/filings/0000950170-23-056381.md) | [22.9](/filings/0000950170-25-047775.md) | [25.3](/filings/0000950170-24-052082.md) | [25.2](/filings/0000950170-24-088584.md) | [27.6](/filings/0000950170-24-118366.md) | [21.7](/filings/0001193125-26-121825.md) | [19.8](/filings/0000950170-25-063543.md) | [17.6](/filings/0000950170-25-103041.md) | [15.6](/filings/0001193125-25-264679.md) | [11.1](/filings/0001193125-26-335085.md) | [9.3](/filings/0001193125-26-217074.md) | [10.5](/filings/0001193125-26-335085.md) |
| Total liabilities | $m | [25.5](/filings/0000950170-23-056381.md) | [30.7](/filings/0000950170-25-047775.md) | [33.2](/filings/0000950170-24-052082.md) | [32.2](/filings/0000950170-24-088584.md) | [34.4](/filings/0000950170-24-118366.md) | [28.4](/filings/0001193125-26-121825.md) | [26.3](/filings/0000950170-25-063543.md) | [45.7](/filings/0000950170-25-103041.md) | [39.6](/filings/0001193125-25-264679.md) | [29.0](/filings/0001193125-26-335085.md) | [27.7](/filings/0001193125-26-217074.md) | [24.7](/filings/0001193125-26-335085.md) |
| Shareholders' equity | $m | [200](/filings/0000950170-24-118366.md) | [169](/filings/0001193125-26-121825.md) | [135](/filings/0001193125-25-264679.md) | [104](/filings/0001193125-25-264679.md) | [76.0](/filings/0001193125-25-264679.md) | [51.6](/filings/0001193125-26-335085.md) | [28.7](/filings/0001193125-26-335085.md) | [27.5](/filings/0001193125-26-335085.md) | [15.6](/filings/0001193125-25-264679.md) | [29.6](/filings/0001193125-26-335085.md) | [18.7](/filings/0001193125-26-335085.md) | [12.1](/filings/0001193125-26-335085.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.9) d](/filings/0000950170-24-118366.md) | [(22.8) d](/filings/0001193125-26-121825.md) | [(32.0)](/filings/0000950170-25-063543.md) | [(32.6) d](/filings/0000950170-25-103041.md) | [(25.2) d](/filings/0001193125-25-264679.md) | [(30.0) d](/filings/0001193125-26-121825.md) | [(25.7)](/filings/0001193125-26-217074.md) | [(19.2) d](/filings/0001193125-26-335085.md) | [(11.6) d](/filings/0001193125-25-264679.md) | [(13.9) d](/filings/0001193125-26-121825.md) | [(11.7)](/filings/0001193125-26-217074.md) | [(10.0) d](/filings/0001193125-26-335085.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-118366.md) | [0.0 d](/filings/0001193125-26-121825.md) | [0.0](/filings/0000950170-25-063543.md) | [0.1 d](/filings/0000950170-25-103041.md) | [0.2 d](/filings/0001193125-25-264679.md) | [0.1 d](/filings/0001193125-26-121825.md) | [0.0](/filings/0000950170-25-063543.md) | [0.0 d](/filings/0000950170-25-103041.md) | [0.0 d](/filings/0001193125-25-264679.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.3](/filings/0000950170-25-047775.md) | [35.7](/filings/0000950170-25-047775.md) | [35.8](/filings/0000950170-25-047775.md) | [35.9](/filings/0000950170-25-063543.md) | [36.0](/filings/0000950170-25-103041.md) | [36.2](/filings/0001193125-25-264679.md) | [36.3](/filings/0000950170-25-047775.md) | [36.6](/filings/0001193125-26-217074.md) | [40.6](/filings/0001193125-26-335085.md) | [59.8](/filings/0001193125-25-264679.md) | [72.3](/filings/0001193125-26-217074.md) | [72.4](/filings/0001193125-26-335085.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,483,852 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335085.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.